<DOC>
	<DOCNO>NCT01151956</DOCNO>
	<brief_summary>Objective : To show dermatologist treat actinic keratoses imiquimod 5 % cream daily clinical routine . Design : Prospective , non-interventional , observational , multicenter clinical study . Setting : Offices 93 non hospital base Austrian dermatologist . Participants : Inclusion 463 patient study solely base treatment decision dermatologist patient . Interventions : No specific intervention except suggested time point visit pre-defined documentation form . The therapy actinic keratoses follow imiquimod label ( 3x/week 4 week , 4 therapy free week , another 3x/week 4 week , need ) Main outcome measure : Information typical imiquimod patient , therapeutic course , treatment decision , safety satisfaction patients/dermatologists .</brief_summary>
	<brief_title>Imiquimod Actinic Keratoses : Observational Study</brief_title>
	<detailed_description>DESIGN AND STUDY POPULATION The present study prospective , open label , non interventional clinical study precisely document routine therapy AK imiquimod 5 % cream . According Austrian regulation , observational study medication follow label drug necessary seek approval federal ethic committee . Except presence multiple AK rule include patient study . Following dermatologist decision patient , 463 patient treat office 93 non hospital base Austrian dermatologist . There intervention except recommended time point visit document pre-defined form . Imiquimod therapy follow label . Patients apply imiquimod home 3x/week ( typically Monday , Wednesday Thursday ) 4 week , follow 4 therapy free week another 3x/week 4 week therapeutic course , need . Recommended visit ( V ) : V1 baseline , week 0 ; V2 , week 4 ( end first treatment cycle ) ; V3 , week 8 ( decision point need second treatment course ) ; V4 , week 16 ( receive second treatment course ) . Additional unplanned visit ( VX ) possible also document . STUDY PROCEDURES At baseline patient characteristic , i.e . sex , age , size weight document together information refer patient dermatologist . Next , patient skin cancer family history AK history include time first presentation well former therapy success ask . This follow dermatological examination define number AK lesion , location nature well intensity initial skin sign ( erosion , crust , erythema , ulceration , swell , others , grade , mild , moderate , severe ) . Before start therapy , patient inform typical imiquimod skin reaction set picture brochure . In addition , patient get treatment plan show different phase therapy time point imiquimod apply . Within plan patient also possibility document imiquimod use . Also baseline , potential systemic local co-medications document . At follow visit , nature intensity Imiquimod relate skin response potential adverse event pre-final termination study acknowledge . Decisions dermatologist document ( ) nature topical post imiquimod treatment therapeutic skin reaction ( V2 , V3 , V4 , VX ) , ( ii ) initiation second therapeutic course , character alternative therapy ( V3 ) well ( iii ) full clearing lesion , number remain lesion ( V3 , V4 ) . At VX dermatologist reaction unplanned visit ask ( consequence , temporary discontinuation therapy - long , topical treatment therapy relate skin symptom , , pre-final termination therapy ) . At end study , reason potential pre-final termination ( lack efficacy , patient wish , adverse event , others ) , kind subsequent therapy remain AK lesion , satisfaction dermatologist efficacy , tolerability cosmetic outcome imiquimod therapy well patient general specific satisfaction cosmetic outcome estimation therapy success include grade relief solve problem delineate .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>study specific , follow label imiquimod study specific , follow label Imiquimod</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>observational study</keyword>
	<keyword>actinic keratosis</keyword>
	<keyword>imiquimod</keyword>
</DOC>